Acute myeloid leukemia is a hematopoietic malignancy caused by recurrent mutations in genes encoding transcriptional, epigenetic and/or signaling regulators. The t(8;21) translocation generates the aberrant transcription factor RUNX1-ETO whose expression can be detected in utero but is insufficient to cause overt disease.
expression in human cells in vitro. However, these experiments suffered from the fact that AML development was slow (Cabezas-Wallscheid et al., 2013) , the proliferation of cells in the culture dish implied the requirement for a selection step (Mandoli et al., 2016; Mulloy et al., 2002 Mulloy et al., , 2003 , RUNX-ETO was induced at higher levels than seen in patients (Mulloy et al., 2002 (Mulloy et al., , 2003 , or assays were performed in established cell lines harbouring additional mutations (Martens et al., 2012; Ptasinska et al., 2012 Ptasinska et al., , 2014 , or in in vitro differentiated yolk sac-like progenitors that are unlikely to represent the proper target cell types (Mandoli et al., 2016) . These caveats hinder the understanding of the earliest, unperturbed epigenetic reprogramming events occurring in a human setting after RUNX1-ETO induction. For this reason, we genetically altered human pluripotent stem cells to inducibly express RUNX1-ETO in response to doxycycline, and used an in vitro system of hematopoietic differentiation that biases cultures towards definitive multipotent hematopoietic progenitor cells (Ng et al., 2016) .
Our experiments showed that high levels of RUNX1-ETO had a detrimental effect on hematopoiesis. However, levels of RUNX1-ETO expression that matched expression of RUNX1 in immature clonogenic blood progenitors were compatible with cell survival. Within 24-hours of RUNX-ETO induction, cells became quiescent, downregulated hematopoietic differentiation, cell cycle and DNA repair genes, but up regulated MAPK and VEGF signalling pathway genes. In contrast to un-induced cells, these cells could survive for months in vitro without proliferating. Strikingly, an enhanced clonogenic capacity of these immature, quiescent RUNX1-ETO expressing cells was only revealed following the removal of doxycycline, ceasing RUNX1-ETO transcription and allowing cells to proliferate and differentiate.
Chromatin immunoprecipitation and chromatin accessibility assays showed that RUNX1-ETO binding led to wide-spread loss of chromatin accessibility at RUNX1 binding sites and substantially altered the RUNX1-controlled transcriptional program.
Single cell RNA-Seq experiments demonstrated that RUNX1-ETO induction exerted its main impact on a defined early precursor population by down-regulating the myeloid master regulator PU.1 but had little effect at later stages or different lineages. Our study therefore sheds light on the earliest events occurring in t(8;21) cells after the first leukemic mutation in a human primary cell setting and demonstrates a dissociation between the block in differentiation and cell proliferation, considered to be the two hallmarks of leukemia.
Results

Expression of RUNX1-ETO leads to a reversible differentiation and growth arrest of human early hematopoietic progenitor cells
In order to analyse the effects of RUNX1-ETO induction in defined cell types, we generated inducible RUNX1-ETO human ESC lines. The parental line used was a previously generated human H9 ESC dual reporter cell line (denoted SOX17 mCHERRY/w RUNX1C GFP/w ) carrying an mCHERRY gene in the SOX17 locus, marking arterial endothelium (Clarke et al., 2013) , and a GFP gene in the RUNX1 locus, resulting in expression of GFP from the distal promoter (RUNX1C) and hence marking hematopoietic stem and progenitor cells (Ng et al., 2016) (Figure S1A ).
RUNX1C is the dominant RUNX1 isoform in fetal liver blood progenitors (Sroczynska et al., 2009) . In contrast to RUNX1B, RUNX1C expression is restricted to hematopoietic cells and defines the subset of CD34+ cells with clonogenic and bone marrow homing activity (Ng et al., 2016) . This strategy allowed us to track the progression of in vitro cell differentiation ( Figures 1A, B , and S1B), facilitating the distinction between endothelial and hematopoietic cells. It also allowed us to monitor the endothelial-hematopoietic transition (EHT), the process by which hematopoietic progenitor cells form and detach from the endothelium which is accompanied by a switch in RUNX1 promoter usage (Bertrand et al., 2010; Boisset et al., 2010; De Bruijn et al., 2002; Jaffredo et al., 1998; Kissa and Herbomel, 2010; Lam et al., 2010; North et al., 2002) . We derived definitive hematopoietic progenitors from ESC lines using a protocol that included SB431542 and CHIR (an ACTIVIN inhibitor and WNT agonist, respectively) from day 2-4 to pattern cells towards an intra-embryonic, definitive HOXA+ fate (Ng et al., 2016) (Fig 1A) . By differentiating the dual reporter cell line using this protocol, we were able to visualize RUNX1C+ progenitors emerging from SOX17+ hemogenic endothelium and forming cell clusters, resembling progenitor formation within the week 5 human aorta-gonad-mesonephros (AGM) (Ng et al., 2016) (Fig 1B, S1B) .
We next generated cell lines containing an N-terminal hemagglutinin (HA)-tagged RUNX1-ETO cDNA, expressed in a doxycycline (Dox)-inducible manner, targeted to the safe harbour AAVS1 locus ( Fig 1C) . Induction of HA-RUNX1-ETO occurred in the vast majority of cells ( Fig S1C, S1D ). We first determined the Dox concentration required to induce RUNX1-ETO expression to levels in hematopoietic progenitors that mimicked the balanced ratio of RUNX1-ETO:RUNX1 expression observed in AML patients ( Fig S1E) , concluding that 3 -5 ng/ml was the most appropriate concentration. Higher Dox concentrations (100-500 ng/ml) that further increased RUNX1-ETO levels completely abrogated blood formation (data not shown). To examine the dose response of hematopoiesis to RUNX1-ETO expression we induced differentiating cells with either 3, 5 or 10 ng/ml Dox ( Fig 1D) . Dox induction before the endothelial to hematopoietic transition (EHT) resulted in severe disorganization of the SOX17+ vasculature and an overall reduction of blood cells that also appeared phenotypically abnormal ( Fig 1E, S1F ). Abnormal progenitors either lacked GFP (RUNX1C) expression, failed to downregulate SOX17 (CHERRY+) or co-expressed both SOX17 and RUNX1C (CHERRY and GFP positive). However, induction after the EHT allowed the generation of phenotypically normal blood cells, with only 10 ng/ml Dox reducing blood cells numbers ( Fig 1G) .
Expression of RUNX1-ETO also affected the nature of the hematopoietic cells present in our cultures causing a Dox-dependent decrease of RUNX1C+ and CD16+ myeloid cells and an increase of CD34+CD38-CD90+ populations resembling immature blood progenitors ( Fig 1G) .
RUNX1-ETO induction reduced colony forming ability in CFU assays in Dox-
containing methylcellulose medium in a dose-dependent manner ( In addition, presence of RUNX1-ETO caused a profound decrease in DNA-synthesis activity due to an arrest in the G1 phase of the cell cycle, as measured by BrDU incorporation, without an increase in cell death ( Fig S1J) .
In summary, our experiments show that the expression of balanced levels of RUNX1-ETO in developing human blood progenitor cells leads to a reversible block in differentiation with growth arrest and prolongation of cell survival.
RUNX1-ETO induction leads to cell-type and dose-dependent changes in gene expression
We previously demonstrated that RUNX1-ETO reshapes the transcriptional network in a developmental stage-specific manner and that the outcome is dependent on the cell type in which the oncogenic event occurs (Regha et al., 2015) . To examine the molecular basis of this finding in human cells, we examined genes induced by RUNX1-ETO in two progenitor cell populations (SOX17 -CD45 + CD34 + RUNX1C +(GFP+) ) and SOX17 -CD45 + CD34 + RUNX1C -(GFP-) ) isolated from d22 differentiating cultures with or without prior induction of RUNX-ETO by 24 hours of doxycycline treatment ( Fig S2A) . Both populations comprised CD34+CD45+
progenitors but the molecular distinction between RUNX1C+ and RUNX1Cpopulations was not known. Analysis of differential gene expression between RUNX1C+ and RUNX1-cells showed over 500 and 600 genes up-and downregulated, respectively, demonstrating an intrinsically different nature of the two cell populations ( Fig S2B) . Expression levels of RUNX1 and SPI1 were similar but RUNX1C-cells expressed high levels of monocyte-specific genes such as IRF8, CSF1R and CD14 indicating the presence of maturing myelomonocytic cells (Supplemental dataset 2). RUNX1C+ cells expressed higher levels of MYB, GATA2
and GFI1 as well as the erythroid regulators GATA1 and KLF1. After induction of RUNX1-ETO with 5 ng/ml Dox, both RUNX1C-and RUNX1C+ cell populations upand down-regulated similar number of genes ( Fig S2C) . The actual RUNX1-ETO responsive gene expression program was also different ( Fig 3A, Supplementary Dataset 3). In accordance, up-and down-regulated KEGG pathways in gene sets from cells responding to 5 ng/ml or 10 ng/ml Dox induction differed as well ( Fig 3B, Supplementary Dataset 4). RUNX1C+ cells down-regulated cell cycle and DNAreplication genes (such as BRCA1, BUB1B and RNASEH2B) and up-regulated a large number of signalling genes (such as MAPK3 and JUN), whilst RUNX1C-cells down-regulated genes belonging to hematopoietic lineage pathways (such as CEBPA, IL4 and KIT) and up-regulated only a subset of the genes upregulated in the RUNX1C+ population. Moreover, the gene expression response to RUNX1-ETO induction in RUNX1C+ cells was highly dose-dependent ( Fig 3C, S2D ). Furthermore,
RUNX1-ETO induction yielded highly heterogeneous changes in gene expression
with distinct subsets of genes responding differently to the oncogene dosage ( Fig   S2E) . For example, expression of the stem cell regulator GATA2 and the WT1 gene, decreased, along with cell cycle genes (BUB1, CHEK2, CCNB1) and the growth factor receptor gene KIT ( Fig 3D) . In contrast, genes involved in signalling pathways (MAPK3) and immediate early response genes (FOS, JUN) were up-regulated ( Fig   3D) . These gene expression data were concordant with the observed cell cycle arrest and demonstrate that RUNX1-ETO impacts on distinct cell types in a different fashion, highlighting the importance of inducing RUNX1-ETO in the appropriate cell type for the understanding of the leukemic phenotype.
RUNX1-ETO induction causes extensive global chromatin reorganisation and disrupts the binding of RUNX1 at distal elements
In order to understand the RUNX1-ETO-mediated chromatin reprogramming and changes in transcription factor binding in RUNX1C+ binding across all RUNX1-ETO bound sites as well as a reduction of the active histone marks H3K27 acetylation (Ac) and H3K4 trimethylation (me3) ( Fig 4B, Fig   4E) . These losses were most pronounced on distal elements (Fig S3 C, D) whereas promoters were less affected (Fig S3 A, B ).
The binding pattern of RUNX1-ETO showed a large overlap with that of RUNX1 and the majority of genes bound by both factors lost RUNX1 binding after RUNX1-ETO induction ( Fig S3E, green circle) . Around 40% of both upregulated and downregulated genes upon induction were RUNX-ETO target genes ( Figure S3F ).
Moreover, approximately half of the downregulated and upregulated RUNX-ETO target genes were also RUNX1 targets that would lose RUNX1 binding upon induction (Supplemental Dataset 5). However, a small proportion of the differentially expressed RUNX1 targets that lose binding upon induction, do not appear to be targeted by RUNX1-ETO ( Figure S3F , light colours). Taken together, our data demonstrate that induction of RUNX1-ETO dramatically alters the RUNX1 driven gene expression program, mostly by direct, but also by indirect means.
Human ESC-derived multipotent progenitor cells are transcriptionally similar to the first preHSCs developing from the human AGM (Ng et al., 2016) . However, changes in the chromatin structure often precede the onset of transcription (Bonifer and Cockerill, 2017) . We therefore wished to determine to what extent the chromatin landscape in our human ESC-derived progenitors resembled that of normal blood stem and progenitor cells. To this end, we compared our ATAC-Seq data derived from un-induced and induced cells to those generated from highly purified human hematopoietic precursor populations as well as monocytic cells (Corces et al., 2016) ( Fig 4F) . This analysis shows a strong resemblance of the overall ATAC-Seq pattern of human ESC-derived RUNX1C+ progenitors to HSC and MPP populations, but not to monocytes. RUNX1-ETO induction completely shifted this pattern, resulting in loss of open chromatin regions specific for early progenitors and appearance of new accessible sites. In human ESC-derived progenitors, RUNX1-ETO induction deregulated a similar set of genes as that found in t(8;21) AML patients when compared to normal CD34+ stem/progenitor cells ( Fig 4G) . This result argues that the initial RUNX-ETO mutation may account for a large portion of the altered transcriptional network in leukemia patient samples.
RUNX1-ETO expression blocks the differentiation of a specific cell population
To identify the cells most responsive to RUNX1-ETO induction, we performed single showed a strong arrest in the G1 phase of the cell cycle ( Fig 5C) . Some degree of cell cycle arrest was also observed in the stem/progenitor, eosinophil and GMP-like populations (orange / purple / dark blue) but not in the erythroid (pink / red) populations. A similar result was also seen when we measured the number of genes responding to induction ( Fig S4E) , with the population with highest number of changing genes being the 5-Dox enriched new cell population (green), followed by the stem/progenitor population (orange) and lastly the erythroid lineage (pink and red), which showed only few responsive genes. We next projected the expression of important hematopoietic regulator genes on the different cell clusters ( Fig 5D) . This analysis demonstrated again the cell-type specificity of the response to RUNX1-ETO induction, since genes were differently regulated on the distinct cell clusters. The quantification of expression of individual genes ( Fig S5) in the different clusters showed that the most dramatic response was the loss of SPI1 (PU.1) expression in the 5-Dox enriched population, as well as strongly upregulated expression of the SOX4 transcription factor gene. We also observed a reduction of GATA2, CEBPA and GFI1B expression. Interestingly, cells in the 5-Dox enriched population expressed the chemokine gene CCL5, which has roles in proliferation, metastasis and in creating an immunosuppressive environment. As shown above, transcription factors relevant for erythroid development and erythroid genes were largely unaffected, as were other genes such as MEIS1. Gene expression and KEGG pathway analysis of up-and down regulated genes in the 5-Dox enriched population are consistent with the results obtained from the bulk RNA-Seq data ( Fig S6A,B , Supplemental Dataset 7). These results show that single cell analysis of RUNX1-ETO transcriptional dysregulation yielded similar results to the differential gene expression observed in the bulk progenitor population upon 5 Dox treatment, confirming the RUNX1-ETO-dependent down-regulation of cell cycle, replication, and interestingly, spliceosome and ribosomal genes.
To gain more insight into the position of RUNX1-ETO-responsive cell population within the differentiation trajectory, we performed a pseudotime (nearest neighbour) analysis ( Fig 6) . Un-induced cells showed a clear distribution of the different populations with the stem-like (orange) population at the apex of the hierarchy from which the erythroid and myeloid lineages branched ( Fig 6A, left panel). Induction of RUNX1-ETO distorted this differentiation trajectory ( Fig 6A, right panel). The myeloid and stem-like arms were disorganised, with cells from different clusters scattered over the trajectory, although the erythroid branch appeared unaffected. Our results are consistent with RUNX1-ETO halting differentiation with cells forming a continuum of mixed differentiation stages rather than a trajectory, which would be in agreement with the fact that cell cycle is blocked and lineage fate decisions cannot be properly executed. The same scenario can be seen when the expression of specific genes in the different cell populations is projected on the trajectory ( Fig 6B) . The expression of genes such as GATA2 and SPI1 (PU.1) scattered all over the trajectory after induction ( Fig 6B) and their expression was down-regulated in stem-like (orange) and 5-Dox enriched (green) populations ( Fig   6B, Fig S5) . However, the analysis of SPI1 (PU.1) expression in monocytic cells (purple) showed a different picture ( Fig 6B, S5) , as SPI1 appeared to be much less perturbed by RUNX1-ETO induction, suggesting that cells that have passed a certain differentiation state become less sensitive to perturbation. This might be explained due to additional enhancers that are not dependent on prior expression of RUNX1 (Leddin et al., 2011) . In contrast, SOX4 upregulation is confined to the stem-like and the 5-Dox induced cell population ( Fig S5) .
Taken together, our results are consistent with the finding that RUNX1-ETO reprograms a specific, strongly responsive early myeloid cell population, leading to the dysregulation of genes involved in stem/progenitor cell development and arrested differentiation as well as growth of these cells.
Discussion
RUNX1-ETO induction at balanced levels in human progenitor cells induces quiescence and promotes their survival
The t(8;21) translocation can be observed in utero and RUNX1-ETO-expressing clones can be detected in post-natal blood samples, suggesting that cells that acquired the mutation might form a pre-leukemic clonal reservoir (Wiemels et al., 2010) . Our laboratories have established a protocol for the generation of CD34+ RUNX1C+ definitive hematopoietic progenitors arising from HOXA+ hemogenic vasculature, that resemble cells arising during human intra-embryonic hematopoiesis within the AGM region (Ng et al., 2016) . These progenitors present similar transcriptional profiles, cell surface receptors and signaling molecules to cells sorted from human AGM. The work presented here demonstrates that such cells also display an accessible chromatin landscape resembling the HSC/MPP pattern found in adult hematopoietic cells.
In agreement with previous experiments in murine ESCs (Regha et al., 2015) , RUNX1-ETO expression at a high levels in differentiating human ESCs abrogated blood formation and here we show that it also perturbs vasculogenesis, similar to what has been shown in transgenic mice (Yergeau et al., 1997) . Expression of RUNX1-ETO before the EHT, even at an equivalent level to that of endogenous RUNX1, caused a dramatic disorganization of vascular structures and formation of morphologically abnormal hematopoietic progenitors. However, induction of the same level of RUNX1-ETO after the EHT allowed the formation of progenitor cells, but promoted the accumulation of a cell population expressing markers of immature blood progenitors with a CD34+CD38-CD90+ phenotype. This CD34+CD38-CD90+CD45+RUNX1+ signature in our RUNX1-ETO-expressing progenitors is shared with an embryonic population of cells containing the first few definitive human
HSCs (Ivanovs et al., 2014) .
Balanced levels of RUNX1-ETO expression (i) do not block blood formation, (ii) confer survival but not proliferation to a subset of progenitors, (iii) do not cause apoptosis (data not shown) and (vi) maintain cells in a quiescent stage. Moreover, the latent colony forming activity of progenitors that had been previously rendered quiescent by RUNX1-ETO induction re-emerged upon removal of Dox from the methylcellulose CFU assay. Indeed, these cells exhibited a higher yield of colonies when compared to their uninduced counterparts, suggesting that the blocked differentiation state is reversible even after extended RUNX1-ETO expression in culture. This result is consistent with prior re-plating assays of RUNX-ETOexpressing mouse bone marrow cells which showed an increase of self-renewal but not proliferation (Rhoades et al., 2000) . Our observations are also consistent with the idea of the existence of a reservoir of cells harbouring the t(8;21) translocation in a quiescent pre-leukemic state, as reported by the presence of a small population of HSC harbouring the translocation in t(8;21) patients in remission (Shima et al., 2014) . In contrast, studies using retroviral transduction of human CD34+ cord blood hematopoietic cells to constitutively express RUNX1-ETO were reported to enhance in vitro proliferation, whilst maintaining self-renewal and differentiation capacity (Mulloy et al., 2002 (Mulloy et al., , 2003 . These discrepancies might be explained by differences in the expression levels of RUNX1-ETO used and/or by selection of specific clones of cells that were outgrowing in culture (Mulloy et al., 2002 (Mulloy et al., , 2003 , indicating that the growth arrest can be surpassed. A dual role of RUNX1-ETO in blocking differentiation and arresting cell growth has been previously described , although they observed that RUNX1-ETO-dependent growth arrest resulted in apoptosis. It is important to note that those studies were conducted in a cell line (U937) representing a different type of AML, and probably carrying additional oncogenic mutations, suggesting that RUNX1-ETO cannot reprogram one leukemic cell type into another. This observation is consistent with previous work from our lab that showed that each leukemogenic mutation directs hematopoietic precursors through a different developmental path (Assi et al., 2019) .
RUNX1-ETO induction causes extensive global chromatin reorganisation and shuts down the RUNX1-directed gene expression program
We found that the pattern of up and down-regulated RUNX1-ETO target genes is tightly correlated to changes observed in t (8;21) AML cells that show that high CDK6 and CCND1/2 expression levels are dependent on the AP-1 transcription factor family, which mediates MAPK signalling and whose expression, in turn, depends on the presence of RUNX1-ETO (Martinez-Soria et al., 2019) . Moreover, AP-1 is a critical factor for the establishment of t(8;21) AML in xenotransplantation experiments (Assi et al., 2019) . In order to develop overt disease, RUNX1-ETO cooperates with mutated growth factor receptors, such as KIT or FLT3 (Schessl et al., 2005; Wichmann et al., 2015) , indicating that such mutations may act upon an already partially activated signalling landscape. So far, we have not been able to grow RUNX1-ETO-transduced human cells without an extensive selection and outgrowth in culture (unpublished results), indicating that we do not yet understand which signals are essential and responsible for the epigenetic drift that permits growth in vitro.
Changes in gene expression after induction of RUNX1-ETO were mediated by rapid reorganisation of the epigenetic landscape, leading to loss of accessibility of thousands of sites enriched in RUNX motifs and bound by RUNX1, although RUNX1 expression per se was not affected. Concomitantly, H3K27 acetylation was reduced, demonstrating that binding of RUNX1-ETO directly interferes with that of RUNX1.
Interestingly, these changes were most pronounced at distal elements. It is now clear that cellular identity is encoded within the combination of active distal elements (Corces et al., 2016; Heinz et al., 2010) , which demonstrates that RUNX1-ETO profoundly and rapidly interferes with the identity of its target cells.
It has been shown that t(8;21) cells are absolutely dependent on the presence of a normal RUNX1 allele, which is required to balance the detrimental effects of RUNX1-ETO expression by upregulating critical mitotic checkpoint genes (Ben-Ami et al., 2013; Loke et al., 2017) . It is therefore possible that restoring the growth of RUNX1-ETO-induced cells requires the re-establishment of, at least, part of the RUNX1-mediated gene expression program. This is likely to include the expression of SPI1 (PU.1) (Huang et al., 2008) or CEBPA, but also genes that override the RUNX1-ETO mediated cell cycle block.
RUNX1-ETO expression blocks the differentiation of a specific cell population
Reprogramming of one cell fate into another requires a complete reorganisation of the epigenome and is facilitated by reprogramming cells within a similar developmental pathway (Graf and Enver, 2009 ), but can also be enforced upon cells from different pathways by overexpression of complementary transcription factors (Takahashi and Yamanaka, 2006) . One of the most important and unanswered questions in AML research is the understanding of the nature of the target cells that are susceptible to transformation in order to understand the first response to an oncogenic hit. This notion is exemplified by our finding that RUNX1C-and RUNX1C+ cells significantly differ in their response to the expression of the fusion protein. Our scRNA-Seq data clearly demonstrate that only early multipotent myeloid precursors respond to RUNX1-ETO induction. Moreover, those are the only cells suffering a down-regulation of the myeloid master regulator PU.1, without which myelopoiesis is strongly perturbed (McKercher et al., 1996; Scott et al., 1994) , providing a molecular explanation for the RUNX1-ETO-mediated differentiation block. Expression of RUNX1-ETO also leads to an upregulation of SOX4 in the 5-Dox enriched cell cluster, which is consistent with the down-regulation of CEBPA. SOX4 expression is required for self-renewal of HSCs as well as LSCs, and its expression has been shown to be upregulated in HSCs from CEBPA-null mice and in patients with abnormal C/EBPa function (Zhang et al., 2013) , and thus with myelopoiesis.
In summary, we have shown that we can use the differentiation of human ES cells into definitive hematopoietic progenitor cells to gain insight into the earliest events of epigenetic reprogramming by RUNX1-ETO and its interplay with RUNX1 in a human embryonic setting. Our future experiments are aimed at further understanding the nature of the growth stimulus required to overcome RUNX1-ETOmediated growth arrest.
Experimental Procedures
Generation and validation of targeted inducible RUNX1-ETO SOX17 mCHERRY/w RUNX1C GFP/w hESC lines
The dual reporter SOX17 mCHERRY/w RUNX1C GFP/w hESC H9 line was previously generated by us (Ng et al., 2016) . 
Maintenance and hematopoietic differentiation of hESC
Culture and enzymatic passaging of hESC lines was conducted as previously reported (Ng et al., 2008) . Hematopoietic differentiation of hPSCs was performed following the spin Embryo Body (EB) method in STAPEL medium (Ng et al., 2008) with supplements used as reported (Ng et al., 2016) with some modifications, detailed in Supplemental methods.
Colony-forming assays
Colony-forming-unit (CFU) assays were performed as reported (Ng et al., 2016) with some modifications. Briefly, 3-5 x 10 3 cells were cultured in 1% methylcellulose, supplemented with the '5-factor' cytokine mix (as used in the hematopoietic differentiation) plus 10 μg/ml human low-density lipoproteins (hLDL, Stem Cell Technologies cat# 02698) and 5 U/ml erythropoietin (EPO, PeproTech cat# 100-64).
For the preparation of 1% methylcellulose, 40 ml serum-free 2.6% MethoCult TM H4100 (Stem Cell Technologies #01400) was mixed with an equal volume of 2x STAPEL-P medium (STAPEL medium made with IMDM containing 2x supplements and without PFHMII) plus 20 ml of 1x STAPEL medium to give a final volume of 100 ml. Cells were cultured either with or without Dox and each condition was set up in triplicates in ultra-low attachment 24-well plates (cat# NUN144530). Plates were scored for hematopoietic CFUs after 7 to 10 days.
Replating assays
Replating assays were conducted on non-adherent hematopoietic progenitors plated at a known concentration on Matrigel-coated wells of a 6-well plate. Cells were harvested, counted and replated weekly. Live and death cells were determined using a FL Countess-II Automated Cell Counter (Thermo Fisher Scientific) after Tripan-Blue staining.
RNA-Seq library preparation
RNA-sequencing (seq) libraries were prepared using a TruSeq® Stranded mRNA For other details see Supplemental methods.
Chromatin Immunoprecipitation with high-throughput sequencing (ChIP-Seq)
ChIP was performed on CD34+ magnetic sorted samples (RUNX1-ETO and RUNX) and on non-adhered floating mixed progenitors (H3K4me3 and H3K27ac) after single crosslink, as reported (Obier et al., 2016) .
Single Cell RNA-Seq (scRNA-Seq)
Non-adherent progenitors at day 22 of differentiation (untreated and 24-hour Dox treatment) were sorted for CD45+ CD34+ and RUNX1C+. Cells were re-suspended in 80 μl at a concentration of 100-1200 cells/μl for evaluation of cell viability prior to loading of 4000 single cells on a Chromium Single Cell Instrument (10X Genomics).
Library generation for scRNA-seq was performed by the Genomics Birmingham
Sequencing Facility using the Chromium Single Cell 3′ Library and Gel Bead Kit v2 (10X Genomics). Libraries were paired-end sequenced on an Illumina NextSeq machine using the cycle parameters recommended by 10X Genomics.
Statistical analysis
Experiments were analysed using GraphPad Prism versions 5-7 (GraphPad Software Inc.) and Microsoft Excel (Microsoft corporation).
Bioinformatic Data processing and analysis:
Details of data analysis iare described in Supplemental Methods.
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